Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 2/20 | 0.32 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.31 |
| ▸ | FPR3 | P25089 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26494358 | 0.94 | L3MBTL1 (0.33) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL22957198 | 0.90 | PDK2 (0.37) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL224144 | 0.90 | HDAC6 (0.37) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL18755717 | 0.86 | CA14 (0.35) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL21998123 | 0.85 | TSHR (0.38) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL31634922 | 0.84 | L3MBTL1 (0.36) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL21997101 | 0.84 | L3MBTL1 (0.36) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL21996785 | 0.84 | CA14 (0.36) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL7227365 | 0.83 | CA14 (0.40) | L3MBTL1CA14HDAC1HDAC2HDAC6 | |
| SCHEMBL22276510 | 0.83 | PDK2 (0.40) | L3MBTL1CA14HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4504694-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | Capstan Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20240299311-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2024-09-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196444-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196444-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | L3MBTL1 98/4885CA14 3020/4885HDAC1 1169/4885 |
| US-20240299311-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | L3MBTL1 98/4885CA14 3020/4885HDAC1 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.